EN
DE
Home
About us
Biofronteras Expertise
Management and supervisory board
Product Pipeline
Clinical trials
Products
Product Portfolio
Investors
Key stock information
Financial reports
Financial announcements
Shareholder structure
Corporate calendar
Corporate governance
Annual general meeting
SEC reporting
FAQs Delisting BFRA
Takeover Offer of Deutsche Balaton AG
Presentations & contact
Career
Careers
Contact
Biofrontera
Investors
Financial announcements
Latest News Releases
01/18/2023 11:50
PTA-News: Biofrontera AG: Start of Phase 3 Clinical Trial in the US for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk
01/12/2023 11:30
PTA-News: Biofrontera AG: Biofrontera receives notice of allowance for US patent on innovative photodynamic treatment protocol
01/06/2023 08:25
PTA-News: Biofrontera AG: Court Rules 2021 Executive Board and Supervisory Board Resolutions Concerning IPO of Biofrontera Inc. To Be Unlawful
12/19/2022 14:05
PTA-News: Biofrontera AG: Commercial launch of Ameluz® in Finland
12/08/2022 13:55
PTA-News: Biofrontera AG: Biofrontera establishes UK subsidiary to strengthen its sales activities in the country
11/23/2022 15:00
PTA-News: Biofrontera AG: Biofrontera reports on business development in the third quarter and the first nine months of 2022
11/21/2022 21:50
PTA-Adhoc: Biofrontera AG: Biofrontera is going to submit proposal for resolution on capital increase at an extraordinary shareholders' meeting
11/16/2022 12:35
PTA-News: Biofrontera AG: Biofrontera AG strengthens international marketing and sales activities
11/11/2022 18:10
PTA-Adhoc: Biofrontera AG: Biofrontera AG reports result of the capital increase resolved on April 07, 2022
10/26/2022 08:40
PTA-News: Biofrontera AG: Subscription offer for up to 7,089,673 new shares begins on October 28, 2022
Financial announcements
Material News
Current & Archive (Related Party Transactions incl.)
Corporate News
Current & Archive
Voting Rights
Notifications
Current & Archive
Directors' Dealings
Current & Archive
